首页> 外文OA文献 >LB0001 MAVRILIMUMAB IMPROVES OUTCOMES IN PHASE 2 TRIAL IN NON-MECHANICALLY-VENTILATED PATIENTS WITH SEVERE COVID-19 PNEUMONIA AND SYSTEMIC HYPERINFLAMMATION

【2h】

LB0001 MAVRILIMUMAB IMPROVES OUTCOMES IN PHASE 2 TRIAL IN NON-MECHANICALLY-VENTILATED PATIENTS WITH SEVERE COVID-19 PNEUMONIA AND SYSTEMIC HYPERINFLAMMATION

机译：LB0001 Mavrilimumab在非机械通风患者的严重Covid-19肺炎和全身高炎症患者中改善了第2阶段试验的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
L. Pupim; T. S. Wang; K. Hudock; J. Denson; N. Fourie; L. Hercilla Vasquez; K. Luz; M. Madjid; K. Mcharry; J. F. Saraiva; E. Tobar; T. Zhou; M. Samant; J. Pirrello; F. Fang; J. F. Paolini; A. Pano; B. C. Trapnell;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: The TACROVID trial protocol [J] . X. Solanich, A. Antolí, N. Padullés, Contemporary Clinical Trials Communications . 2021,第a期

机译：务实，开放标签，单中心，随机的期第二阶段临床试验，以评估甲基己酮脉冲脉冲和躯干蛋白患者的严重肺炎患者的疗效和安全性 - 19：TACROVID试验方案
2. INTRAVENOUS INFUSION OF CHINESE MEDICINE XUEBIJING SIGNIFICANTLY IMPROVED OUTCOME IN SEVERE PNEUMONIA PATIENTS IN A MULTIPLE CENTER RANDOMIZED DOUBLE BLINDED CONTROLLED CLINICAL TRIAL [J] . Song Y., Yao C., Shang H., Respirology : . 2016,第Suppla3期

机译：多中心双盲双盲临床试验对重度肺炎患者静脉输注中药血必净的效果显着改善
3. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: Results from PROGRESS, an open-label Phase IIIB trial [J] . British Journal of Dermatology . 2012,第6期

机译：将对其他全身疗法反应欠佳的牛皮癣患者改用阿达木单抗后，睡眠质量和其他患者报告的结局改善：PROGRESS的结果，一项开放性IIIB期临床试验
4. RISK-ADAPTED INTRAVENOUS MELPHALAN WITH ADJUVANT THALIDOMIDE AND DEXAMETHASONE FOR NEWLY DIAGNOSED UNTREATED PATIENTS WITH SYSTEMIC AL AMYLOIDOSIS: INTERIM REPORT OF A PHASE II TRIAL [C] . RL Comenzo, P Zhou, L Reich, International Symposium on Amyloidosis . 2005

机译：风险适应的静脉内莫尔甘蔗用佐剂沙利度胺和地塞米松，用于新诊断的未经治疗的全身淀粉样蛋白症患者：II期试验的中期报告
5. Nutritional Risk in the Cancer Patient 65 and Older Undergoing Systemic Treatment via Phase I Clinical Trials [D] . Williams, Anna Cathy. 2019

机译：癌症患者65岁及以上经受I期临床试验的营养风险
6. Pragmatic open-label single-center randomized phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: The TACROVID trial protocol [O] . X. Solanich, A. Antolí, N. Padullés, 2021

机译：务实开放标签单中心随机第II期临床试验评价甲基己酮脉冲脉冲和躯干素的疗效和安全性在患有Covid-19的严重肺炎患者中的疗效和安全性：TaCrovid试验方案
7. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study [O] . Giacomo De Luca, Giulio Cavalli, Corrado Campochiaro, 2020

机译：GM-CSF封锁与严重的Covid-19肺炎和全身性高血液中的Mavrilimumab：单一中心，前瞻性队列研究

LB0001 MAVRILIMUMAB IMPROVES OUTCOMES IN PHASE 2 TRIAL IN NON-MECHANICALLY-VENTILATED PATIENTS WITH SEVERE COVID-19 PNEUMONIA AND SYSTEMIC HYPERINFLAMMATION

著录项

引文网络

相似文献

相关主题

期刊订阅